Phospho-eNOS (Thr113) Polyclonal Antibody, Cy5 Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-3589R-Cy5 |
| Product Name | Phospho-eNOS (Thr113) Polyclonal Antibody, Cy5 Conjugated |
| Applications |
WB
FCM
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Specificity | This phosphorylation site is homologous across the listed species; this phosphorylation site does not exist in human due to a Thr-Ser substitution. |
| Reactivity | Human |
| Predicted Reactivity | Mouse, Rat, Dog, Rabbit |
| Specifications | |
| Conjugation | Cy5 |
| Host | Rabbit |
| Source | KLH conjugated synthetic phosphopeptide derived from mouse eNOS around the phosphorylation site of Ser113 |
| Modification Site | Thr113 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 18127 |
| Swiss Prot | P70313 |
| Subcellular location | Cytoplasm, Cell membrane |
| Synonyms | eNOS; Nos-3; ecNOS; 2310065A03Rik; Nitric oxide synthase, endothelial; Constitutive NOS; cNOS; EC-NOS; Endothelial NOS; NOS type III; NOSIII; Nos3 |
| Background | Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets. May play a significant role in normal and abnormal limb development. |
| Application Dilution | |
| WB | 1:300-5000 |
| FCM | 1:20-100 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |